Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
non-targeting locked nucleic acid
- Development stage
- Preclinical
- Lead developer
- Vanderbilt University Medical Center
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Non-targeting locked nucleic acid (nt-LNA) is an experimental synthetic oligonucleotide therapeutic that acts as an antagonist of Toll-like receptor 8 (TLR8). Developed by researchers at Vanderbilt University Medical Center, nt-LNA is designed to block the activation of TLR8 by microbial small RNAs (msRNAs) which are transported by low-density lipoproteins (LDL). In macrophages, this activation leads to pro-inflammatory polarization and contributes to the progression of atherosclerosis. Preclinical studies in mouse models (*Apoe-/-* and *Ldlr-/-*) have demonstrated that nt-LNA treatment can reduce plaque burden and promote the regression of advanced atherosclerotic lesions, suggesting a potential novel therapeutic approach for cardiovascular disease by targeting the LDL-msRNA-TLR8 axis.
- Other names
- non-targeting LNA
02
Targets
TLR8 (Toll-like receptor 8)
Beyond the preview
Go deeper on non-targeting locked nucleic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on non-targeting locked nucleic acid.